Structural Heart > TAVI Portfolio > ACURATE neo2 > Investigator Initiated Studies



 

The largest real-world comparison of ACURATE neo™ self-expanding valve and SAPIEN 3 balloon expandable valve

60% Risk of PPI icon
-62% Mean Gradient icon
 

 

1st comparison of ACURATE neo self-expanding valve and SAPIEN 3 balloon expandable valve in patients with small annuli.

-62% Mean Gradient icon
-86% Severe PPM icon
 

 

An analysis of 249 patients treated using a minimalist approach with ACURATE neo and SAPIEN 3, to assess the success rate and safety of NDD at 90 days and 1 year post procedure. 

60% next day discharge success icon
9.2% Device Failure, compared to 6.2% SAPIEN icon
60% Risk of PPI icon
 

 

Analysis of 296 patients with pre-existing complete RBBB comparing ACURATE neo and SAPIEN 3, including a propensity-matched population of 130 patients.

 

 

 

 

 


 

An international, multicenter registry comparing the performance of ACURATE neo and Evolut PRO in 1,551 patients

 

9.2% Device Failure, compared to 6.2% SAPIEN icon
safety composite endpoint

 

 

 


 

A single-center trial evaluating the impact of valve selection on procedural outcomes
and length of stay after TAVI in 231 patients. Clinical result after multivariable adjustment, post operative LoS before discharge. 

 

-86% Severe PPM icon
early discharge icon
 

 
 

Sign Up

Get exclusive product updates, training and educational opportunities, and more.
Top